IL-4 and IL-13 are key drivers of Type 2 inflammation in severe asthma1–4

Type 2 cytokines drive the recruitment of effector cells (e.g. eosinophils) and mediate class switching of B cells to secrete IgE upon exposure to antigens5

Hallmarks of Type 2 pathway activation include IgE production and eosinophilia6

The Type 2 cytokine IL-4 drives the differentiation and clonal expansion of Th cells6

IL-4 and IL-13 are primarily responsible for isotype class switching of B cells to produce IgE6

IL-13 effects include mucus secretion, smooth muscle contractility and hyperplasia6

Adapted from Robinson D et al. 2017,5 Gandhi NA et al. 2016,6 Krings JG et al. 2019,7 Lambrecht BN and Hammad H 2015,8 Fahy J. 2015,9 and Le Floc’h A et al. 2020.10

How does DUPIXENT target Type 2 inflammation in severe asthma?

EXPLORE THE DATA

Mode of action DUPIXENT

Have questions about how DUPIXENT works?

 

Find out more

DUPIXENT efficacy

How effective is DUPIXENT in treating your severe asthma patients?


Find out more

Safety profile

Learn more about the safety profile of DUPIXENT.

 

Find out more

    IgE, Immunoglobulin E; IL, interleukin; ILC, innate lymphoid cells; PGD2, Prostaglandin D2; Th, T-helper.

    References

    1. Tran TN, et al. Ann Allergy Asthma Immunol. 2016;116(1):37–42.
    2. Seys SF, et al. Respir Res. 2017;18:39.
    3. Peters MC, et al. J Allergy Clin Immunol. 2014;133(2):388–394.
    4. Doran E, et al. Front Med. 2017;4:139.
    5. Robinson D, et al. Clin Exp Allergy. 2017;47(2):161–175.
    6. Gandhi NA, et al. Nat Rev Drug Discov. 2016;15:35–50.
    7. Krings JG, et al. J Allergy Clin Immunol Pract. 2019;7(5):1379–1392.
    8. Lambrecht BN and Hammad H. Nat Immunol. 2015;16(1):45–46.
    9. Fahy JV. Nat Rev Immunol. 2015;15(1):57–65.
    10. Le Floc’h A, et al. Allergy. 2020;75(5):1188–1204.

MAT-GB-2004973 (v8.0) | Date of preparation: May 2023.